| Identification | Back Directory | [Name]
L-Phenylalaninamide, L-leucyl-L-arginyl-L-arginyl-L-phenylalanyl-L-seryl-L-threonyl-L-alanyl-L-prolyl-L-phenylalanyl-L-alanyl-L-phenylalanyl-L-isoleucyl-L-α-aspartyl-L-isoleucyl-L-asparaginyl-L-α-aspartyl-L-valyl-L-isoleucyl-L-asparaginyl- | [CAS]
2417491-82-6 | [Synonyms]
Gersizangitide
L-Phenylalaninamide, L-leucyl-L-arginyl-L-arginyl-L-phenylalanyl-L-seryl-L-threonyl-L-alanyl-L-prolyl-L-phenylalanyl-L-alanyl-L-phenylalanyl-L-isoleucyl-L-α-aspartyl-L-isoleucyl-L-asparaginyl-L-α-aspartyl-L-valyl-L-isoleucyl-L-asparaginyl- | [Molecular Formula]
C111H167N29O28 | [MOL File]
2417491-82-6.mol | [Molecular Weight]
2355.73 |
| Hazard Information | Back Directory | [Uses]
Gersizangitide (AXT107) is an angiogenic inhibitor peptide containing 20 amino acids.Gersizangitide is a VEGF-A and VEGF-C inhibitor and a Tie2 activator. Gersizangitide is a collagen IV-derived peptide that blocks VEGF receptor signaling and suppresses vascular leakage in ischemic retinopathy and choroidal neovascularization[1]. | [IC 50]
Tie2; VEGF-A; VEGF-C | [References]
[1] Fei X, et al. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration. Arch Pharm Res. 2024 Jun;47(6):538-557. DOI:10.1007/s12272-024-01503-3 |
|
|